Respiratory failure during induction chemotherapy for acute myelomonocytic leukaemia (FAB M4Eo) with Ara‐C and all‐<i>trans</i> retinoic acid

Lester, William A.; Hull, Donald; Fegan, CD; Morris, T. C. M.

doi:10.1046/j.1365-2141.2000.02043.x

Cited by 15 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary damage in myelomonocytic leukemias associating eosinophilia has been linked to eosinophil degranulation [25,26], emphasizing the likelihood of a similar mechanism in acute basophilic leukemia. Consequently, steroid premedication and double histamine receptor blockade was initiated and succeeded to limit the impact of histamine related complications.…”

Section: Discussionmentioning

confidence: 99%

FLT-3 ITD Positive Acute Basophilic Leukemia with Rare Complex Karyotype Presenting with Acute Respiratory Failure: Case Report

Antohe

Dăscălescu

Danaı̈la

et al. 2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

FLT-3 ITD Positive Acute Basophilic Leukemia with Rare Complex Karyotype Presenting with Acute Respiratory Failure: Case Report

Antohe

Dăscălescu

Danaı̈la

et al. 2018

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

“…However, this may be related mainly to complications of induction therapy like tumor lysis syndrome rather than to the biology of the disease. 34 …”

Section: Discussionmentioning

confidence: 99%

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients

et al. 2007

View full text Add to dashboard Cite

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients The spectrum of CBFB-MYH11 fusion transcripts in acute myeloid leukemia (AML) M4eo with inv(16)/t(16;16) is heterogeneous. Approximately 85% show type A CBFB-MYH11 fusion transcripts. In addition, more than 10 different fusion transcripts have been reported. The prognostic impact and biological background of rare fusion transcripts remain open. In this study, a molecular characterization of CBFB-MYH11 transcripts in 162 patients with CBFB-MYH11 positive AML at diagnosis was performed. In total, 128 patients (79.0%) showed the fusion transcript type A, whereas nine different rare CBFB-MYH11 fusion genes were detected in 34 cases (21.0%). Rare fusion transcripts were found more frequently in therapy-related AML (P ¼ 0.0106). Numerical gains of the chromosomes 8, 21 and 22 were more frequently associated with type A (28.3%) than with rare fusions (12.9%) (P ¼ 0.012). Median white blood cell (WBC) count was higher in type A (35.4 G/l; range ¼ 1.1-279 G/l) than in cases with rare types (7.8 G/l; range ¼ 0.8-148.0 G/l) (Po0.0001). Rare fusion transcripts were correlated with an atypical cytomorphology not primarily suggestive for the FAB subtype M4eo (P ¼ 0.0203). Immunophenotype revealed lower CD2, CD13, CD33 and CD90 levels than in type A fusion cases (P ¼ 0.036, 0.002, 0.029 and 0.045, respectively). However, the type of fusion was not an independent prognostic parameter.

show abstract

“…In this context it is noteworthy, that pulmonary differentiation syndrome has been described in CBFβ-MYH11/ABL1 AML – and was reported earlier in two patients with myelomonocytic leukemia (FAB M4eo) with high white blood cell counts at presentation and treated with cytarabine-based induction chemotherapy escalated with all-trans retinoic acid (ATRA) [ 11 ].…”

Section: Resultsmentioning

confidence: 99%

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia

et al. 2018

View full text Add to dashboard Cite

Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Importantly, this effect is mediated via overriding the differentiation blockage of the leukemia clone.In addition, we show that dasatinib is capable to induce pulmonary differentiation syndrome – and therefore needs close monitoring of patients under therapy.

show abstract

Respiratory failure during induction chemotherapy for acute myelomonocytic leukaemia (FAB M4Eo) with Ara‐C and all‐trans retinoic acid

Cited by 15 publications

References 13 publications

FLT-3 ITD Positive Acute Basophilic Leukemia with Rare Complex Karyotype Presenting with Acute Respiratory Failure: Case Report

FLT-3 ITD Positive Acute Basophilic Leukemia with Rare Complex Karyotype Presenting with Acute Respiratory Failure: Case Report

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia

Contact Info

Product

Resources

About